Rome IV Criteria for IBS: A Plain-English Diagnostic Guide

This guide takes the Rome IV criteria for irritable bowel syndrome and translates each piece into language a patient can use. By the end you should be able to read your own symptoms against the criteria, name your subtype, recognise red flags, and know what your doctor should be ordering before they hand you the IBS label.

The Rome IV criteria are the international research-grade definition of irritable bowel syndrome. They were published in 2016 by the Rome Foundation, an international working group of gastroenterologists who maintain the standard for the disorders of gut-brain interaction. Most major bodies (NICE in the UK, the American College of Gastroenterology, the Canadian Association of Gastroenterology) have aligned their guidance with Rome IV.

There are exactly four conditions that must all be true for a Rome IV diagnosis of IBS. Missing any one of them moves you out of the IBS box and into a different working diagnosis (often a related functional bowel disorder, sometimes a structural disease that needs investigation).

1. Recurrent abdominal pain at least one day per week, on average, in the last three months. Frequency is the threshold here. Daily is not required. Constant pain is not required. The threshold is one day per week, averaged over the last three months. Patients who experience pain only twice a month do not meet this criterion regardless of how severe those episodes are.
2. The pain is associated with at least two of three features: related to defecation (relieved by it, worsened by it, or otherwise temporally linked), associated with a change in stool frequency, or associated with a change in stool form. The link to defecation and to stool features is what separates IBS pain from other types of abdominal pain.
3. Symptom onset was at least six months before diagnosis. The three-month frequency rule is measured over the most recent three months, but the symptoms must have started at least six months ago. This rules out acute conditions and post-infectious episodes that have not yet stabilised into a chronic pattern.
4. No red-flag features that would suggest another diagnosis. Rome IV is a positive diagnosis, not a diagnosis of exclusion in the old sense, but it does require the absence of features such as blood in stool, weight loss, anemia, or new onset over age 50. We cover the full red-flag list later in this guide.

Two practical implications fall out of this structure. First, you can self-screen against criteria one through three at home in five minutes; you do not need a specialist for that. Second, criterion four (no red flags) is the part that requires a clinician. Some red flags are obvious (blood in stool), some are subtle (overnight symptoms that wake you from sleep), and some require lab work to detect (iron-deficiency anemia, raised inflammatory markers).

Criterion 1: Why "pain" specifically (not just discomfort)

Rome III (the previous version) allowed the criteria to be met by either pain or discomfort. Rome IV tightened this. The current language requires pain. The change was deliberate. Trials run under Rome III had inconsistent enrollment because patients and clinicians defined "discomfort" differently across countries and clinics. Some patients counted bloating as discomfort. Others counted nausea. By tightening the definition to pain, Rome IV produces a more reproducible cohort and a sharper clinical group.

The practical implication for a patient is that if your dominant complaint is bloating, fullness, nausea, or "general unease in the gut" with no clear pain element, you may not formally meet Rome IV IBS even if your symptoms are real. You may instead fit a related functional bowel disorder (functional abdominal bloating, functional dyspepsia) where the treatment options largely overlap. The label changes; the management often does not.

Criterion 2: What "related to defecation" means clinically

"Related to defecation" can mean three different things in the Rome IV scoring. The pain is relieved by passing stool. The pain is worsened by passing stool. Or the pain is reliably associated in time with a bowel movement, even if neither relieved nor worsened. Any of these counts.

"Change in stool frequency" means a noticeable shift from your personal baseline. It is not a fixed number. A person whose normal pattern is one bowel movement per day may notice a change at three per day or every other day. A person whose normal pattern is three per day may notice a change at one per day or six per day. The change is what counts, not the absolute count.

"Change in stool form" is where the Bristol Stool Scale comes in. Rome IV defines this as a shift in the consistency and shape of the stool, scored against the Bristol scale (covered in the next section). A patient whose stools have shifted from Bristol 4 (smooth, soft, sausage-shaped) to a mixture of Bristol 6 (mushy with ragged edges) and Bristol 2 (lumpy and hard) has clearly met the form-change criterion.

You need at least two of these three to be linked to your pain. One alone is not enough. A patient with weekly abdominal pain that has no consistent relationship to defecation or stool changes does not meet Rome IV IBS, and the workup should look elsewhere.

Criterion 3: The 6-month onset rule and why it matters

The 6-month rule exists to filter out acute conditions, post-infectious episodes that have not stabilised, and short-term flares triggered by identifiable causes (a course of antibiotics, an episode of food poisoning, a stress spike that has now resolved). Many of these self-resolve over weeks to a few months. Diagnosing IBS too early in their course leads to over-labelling and to treatment plans that do not match the actual underlying problem.

The 6-month threshold reflects an empirical observation: patients whose symptoms have persisted past six months are statistically far more likely to be experiencing a chronic functional disorder rather than a self-limiting acute episode. The frequency window (one day per week, three months) sits inside the onset window (six months total). So a patient evaluated today for Rome IV would need to have started having symptoms by late autumn of the previous year, and to have had pain at least one day per week consistently over the last three months.

Criterion 4: The role of red flags

Rome IV is a positive diagnosis, meaning it is built on what is present rather than only on what has been ruled out. But it still relies on the absence of features that would point at structural disease. We cover the full red-flag list in its own section below. The key conceptual point: meeting criteria one through three is necessary but not sufficient. A patient with classic IBS-pattern pain, stool-feature changes, and a six-month history who is also losing weight unintentionally and has overnight diarrhea is not a Rome IV IBS patient. They are someone who needs imaging or scoping first.

For a deeper look at underlying mechanisms in IBS, including visceral hypersensitivity, motility changes, microbiome shifts, and the brain-gut axis, see the dedicated page. The Rome IV criteria define what IBS is. The mechanisms page explains why it happens.

The Bristol Stool Scale is a seven-point visual chart developed at the University of Bristol in 1997 by Heaton and Lewis. It standardises the description of stool form so a clinician and a patient can talk about stools in the same language. Rome IV uses the Bristol scale as the formal way to document "change in stool form" and to assign IBS subtype.

The seven types map onto a continuum from severely constipated (Type 1) to severely watery (Type 7). The two ends of the scale are abnormal. The middle is normal.

• Type 1: Separate hard lumps, like nuts. Hard to pass. Severe constipation pattern.
• Type 2: Sausage-shaped but lumpy. Mild constipation pattern.
• Type 3: Like a sausage but with cracks on the surface. Normal.
• Type 4: Like a sausage or snake, smooth and soft. Normal, often considered ideal.
• Type 5: Soft blobs with clear-cut edges. Slight loose pattern, sometimes normal.
• Type 6: Mushy consistency with ragged edges. Mild diarrhea pattern.
• Type 7: Watery, no solid pieces, entirely liquid. Severe diarrhea pattern.

Two important rules apply when using Bristol for IBS subtyping. First, the percentages are calculated only from days when the patient has at least one bowel movement. Days with no bowel movements are excluded from the calculation. Second, the percentages refer to abnormal stools (Bristol 1-2 for hard, Bristol 6-7 for loose). Bristol 3-5 stools are considered normal and do not count toward either tail. This convention prevents misclassification of a patient whose normal stools are healthy and whose abnormal stools are mostly on one side.

Once Rome IV IBS is confirmed, the next step is sub-classification. This is where the Bristol Stool Scale does its main clinical work. Subtype is assigned by tallying the Bristol type of every stool on every day the patient had a bowel movement, then calculating the proportion in each band.

• IBS-D (diarrhea predominant): More than 25% of stools are Bristol 6 or 7, and less than 25% are Bristol 1 or 2.
• IBS-C (constipation predominant): More than 25% of stools are Bristol 1 or 2, and less than 25% are Bristol 6 or 7.
• IBS-M (mixed): More than 25% of stools are Bristol 1 or 2 and more than 25% are Bristol 6 or 7.
• IBS-U (unsubtyped): The patient meets Rome IV IBS criteria, but the stool pattern does not fit cleanly into D, C, or M (often because abnormal stools are infrequent or the sample is small).

Why subtyping matters for treatment selection

Subtype matters because first-line treatments differ meaningfully across the four groups. A treatment that works well for IBS-D can worsen IBS-C and vice versa. Mismatching is one of the most common reasons patients say "I tried treatment X and it did nothing." They tried the right treatment for the wrong subtype.

In broad strokes (your physician will tailor based on your specific picture):

• IBS-D: First-line options often include a low-FODMAP trial, soluble fibre, loperamide for symptom control, and sometimes a bile-acid binder if bile-acid malabsorption is suspected. Antispasmodics and tricyclic antidepressants (at neuromodulator doses) are common second-line.
• IBS-C: First-line often includes soluble fibre such as psyllium, osmotic laxatives like polyethylene glycol, increased water intake, and sometimes prosecretory agents (linaclotide, lubiprostone). SSRIs are sometimes used as neuromodulators.
• IBS-M: The most challenging subtype because treatments that help one tail can worsen the other. Often handled by treating whichever pattern is currently dominant, plus brain-gut therapies that work across the whole disorder rather than at one tail.
• IBS-U: Treatment is usually directed at the dominant symptom (pain, urgency, distension) rather than at a stool pattern, since the stool data does not give a clear handle.

Brain-gut therapies (cognitive behavioural therapy for IBS and gut-directed hypnotherapy) work across all subtypes because they target the central regulatory pathways rather than the bowel pattern. This is one reason the major guidelines list them as evidence-based options for confirmed IBS regardless of subtype.

For a comparison of how IBS sits next to other conditions on the differential, see the SIBO vs IBS vs IBD differential diagnosis page. Many patients arrive at IBS only after these adjacent conditions have been considered and either ruled out or distinguished.

A surprising amount of what patients (and some clinicians) think the IBS criteria say is actually not in Rome IV. Knowing what is not in the criteria is as useful as knowing what is, because it prevents both over-diagnosis and under-diagnosis.

Bloating alone does not meet Rome IV

Bloating is one of the most common GI complaints in primary care, and it is also one of the most commonly mislabelled. Rome IV lists bloating as a supportive feature of IBS, meaning its presence reinforces the diagnosis once the four core criteria are met, but it is not itself a diagnostic criterion. A patient whose only complaint is bloating, without the pain pattern and without the stool-feature changes, does not meet Rome IV IBS.

Such a patient may instead fit a different Rome IV diagnosis: functional abdominal bloating or distension. Treatment options overlap with IBS (low-FODMAP, gut-brain therapies, certain medications), so the management plan often looks similar even though the formal label is different.

Mucus in stool is supportive, not diagnostic

Mucus in the stool is a frequent finding in IBS and was historically considered a hallmark feature. Rome IV lists it as supportive, in the same category as bloating. Mucus alone, without the pain pattern and stool changes, does not establish IBS. Conversely, the absence of mucus does not rule it out. Many Rome IV IBS patients never report mucus.

"Sensitive stomach" is not a Rome IV diagnosis

"Sensitive stomach" is a colloquial description that maps onto a wide range of underlying conditions: IBS, functional dyspepsia, GERD, food intolerances, post-infectious states, anxiety-driven GI symptoms, and others. It is not a Rome IV category. If your previous clinician used this label, it is worth asking which specific Rome IV functional disorder fits best, because each has different first-line treatments.

Functional dyspepsia and IBS are different (but can co-exist)

Functional dyspepsia is the upper-GI cousin of IBS in the Rome IV framework. Where IBS is defined by lower-GI symptoms (pain related to defecation and stool changes), functional dyspepsia is defined by upper-GI symptoms (early satiety, postprandial fullness, epigastric pain or burning). The two are separate Rome IV diagnoses with separate criteria. A patient can have one, the other, or both. Co-occurrence is common, with roughly a third of IBS patients also meeting criteria for functional dyspepsia.

"Stress causes IBS" is an oversimplification

Rome IV does not list psychological stress as either a criterion or a supportive feature. Stress and IBS interact bidirectionally: stress can worsen symptoms in established IBS, and chronic GI symptoms reliably increase psychological distress, but Rome IV is a symptom-pattern definition, not an etiology definition. Patients sometimes hear "you are stressed" as code for "your symptoms are not real." Rome IV is explicit that the symptoms are real, the disorder is real, and the diagnosis stands on the symptom pattern regardless of psychological state.

The red-flag list (sometimes called "alarm features") is the part of criterion 4. These features do not mean IBS is impossible. They mean that another diagnosis must be considered and reasonably ruled out before IBS is confirmed. The presence of any red flag should prompt expanded investigation, not panic. Many red flags turn out to have benign explanations once worked up.

• Blood in stool. Frank red blood, dark tarry stools, or microscopic blood detected on a fecal occult blood test. Causes range from hemorrhoids and anal fissures (very common, benign) to inflammatory bowel disease, polyps, and colorectal cancer (less common, important to rule out).
• Unintentional weight loss. Losing more than about 5% of body weight over 6-12 months without trying. IBS does not typically cause weight loss because nutrient absorption is intact. Significant unintentional weight loss raises concern for IBD, malabsorption, celiac disease, or malignancy.
• Night-time symptoms. Symptoms that wake you from sleep (urgent diarrhea, severe pain). IBS symptoms typically respect sleep. Persistent overnight symptoms point at inflammatory or structural causes.
• Family history of IBD or colorectal cancer. A first-degree relative with Crohn's disease, ulcerative colitis, or colorectal cancer (especially before age 60) lowers the threshold for endoscopic evaluation.
• Anemia or other lab abnormalities. Iron-deficiency anemia, raised inflammatory markers (CRP, ESR), raised fecal calprotectin, or abnormal liver enzymes. None of these are typical of IBS and each has its own differential.
• New onset over age 50. IBS typically begins in adolescence or early adulthood. New-onset GI symptoms after age 50 carry a higher pre-test probability of structural disease, including colorectal cancer, and warrant endoscopic evaluation in most cases.
• Severe progressive symptoms. A clear pattern of getting steadily worse over weeks to months, especially with new features (fever, vomiting, severe pain), is not the typical IBS course. IBS waxes and wanes; it does not usually march downhill.
• Recent antibiotic use, foreign travel, or known infectious exposure. Triggers for post-infectious IBS, but also for ongoing infection (giardia, C. difficile, parasites) that needs to be ruled out before IBS is assumed.

For a deeper dive into the specific conditions that present like IBS but are not, see the page on conditions misdiagnosed as IBS. Celiac disease, microscopic colitis, bile-acid diarrhea, and SIBO are the most common alternative diagnoses uncovered when red flags trigger expanded workup.

Even in the absence of red flags, most major guidelines recommend a basic panel of investigations before confirming a Rome IV IBS diagnosis. The panel is small, cheap, and high-yield. The reason for doing it up front is efficiency: a thorough first workup is faster and cheaper than three rounds of repeat workups over the next two years when the original diagnosis fails to fit.

Stool calprotectin to rule out IBD

Fecal calprotectin is a stool test that reflects neutrophilic inflammation in the bowel wall. It is the single best non-invasive screen for inflammatory bowel disease in a patient who otherwise looks like IBS. A normal calprotectin (typically under 50 micrograms per gram) makes IBD very unlikely. A raised calprotectin is not specific for IBD (it can also rise with infections, NSAID use, or polyps), but it triggers further evaluation including colonoscopy.

tTG-IgA for celiac disease

Tissue transglutaminase IgA antibody (tTG-IgA) is the screening blood test for celiac disease. Celiac can present with IBS-like symptoms (especially IBS-D and IBS-M), and roughly 1% of the general population has it, with significantly higher prevalence in patients presenting with chronic GI symptoms. Total IgA should be measured at the same time, since selective IgA deficiency makes the tTG test falsely negative.

CBC, CRP, and basic metabolic panel

A complete blood count screens for anemia (which would be a red flag) and for raised white cells (suggesting infection or inflammation). C-reactive protein is a non-specific inflammation marker; a normal CRP makes inflammatory disease less likely. Ferritin, B12, folate, TSH, and basic electrolytes round out the panel and catch common alternative or coexisting conditions.

Stool studies if recent travel or infection

If symptoms started after foreign travel, after a known gastroenteritis episode, or after antibiotic use, stool studies are appropriate. The standard panel covers ova and parasites (with a giardia-specific antigen test, since standard microscopy misses giardia frequently), bacterial culture, and C. difficile toxin if there has been recent antibiotic exposure.

Colonoscopy: indications and when not needed

Routine colonoscopy is not required to diagnose IBS in a patient under 50 with no red flags and a normal initial workup. This point is often misunderstood. The current standard is to reserve colonoscopy for patients with red flags, age over 50 (or earlier if family history is strong), persistent symptoms despite first-line treatment, or specific abnormalities on the basic workup. Patients who insist on a "negative scope" before accepting an IBS label are often advised by their gastroenterologist that the scope adds little to a Rome IV-positive, red-flag-negative presentation.

Why a thorough first workup is more efficient than repeat workups later

The temptation in primary care is to start treatment first and investigate only if the patient does not improve. This pathway has hidden costs. Patients whose first-line IBS treatments fail (which is common, since first-line treatments are not universally effective) end up cycling through the workup six to twelve months later, often having tried and failed multiple medications in the meantime. The compressed alternative is to do the basic panel up front (calprotectin, tTG-IgA, CBC, CRP, basic metabolic), confirm Rome IV positively, then start treatment with a clearer prognosis. Patients tolerate failed treatment trials better when they know the diagnosis is solid.

Once Rome IV IBS is confirmed and a subtype is assigned, treatment selection becomes structured. The major guidelines (NICE, BSG, ACG) recommend a stepped approach: lifestyle and dietary modifications first, targeted medication second, and brain-gut therapies for confirmed Rome IV IBS at any point in the pathway, especially when symptoms are persistent or quality of life is significantly affected.

Subtype-driven treatment selection

As covered earlier, IBS-D, IBS-C, IBS-M, and IBS-U have different first-line treatment lists. The single most useful artifact at this stage is your two-week Bristol diary, because it gives both you and your physician a concrete dataset to choose from rather than a vague impression of "mostly diarrhea" or "mostly constipation."

Lifestyle and dietary first-line approaches

Three dietary approaches have the strongest evidence base in IBS: the low-FODMAP diet, soluble fibre supplementation (especially psyllium), and standard healthy-eating advice with attention to meal timing and portion sizes. The low-FODMAP diet is delivered in three phases (elimination, reintroduction, personalisation) and works best with a registered dietitian. It is not a long-term diet; the goal is to identify personal triggers and then liberalise back to the largest sustainable diet possible.

Medication options by subtype

Medication selection depends on subtype and on the dominant symptom (pain, urgency, distension, constipation). Antispasmodics (peppermint oil, dicyclomine) are commonly first-line for pain. Loperamide is used for IBS-D; PEG 3350 and prosecretory agents for IBS-C. Neuromodulators (tricyclic antidepressants at low doses for IBS-D, SSRIs for IBS-C, SNRIs for chronic pain) are reasonable second-line options that target the central component of the disorder.

Brain-gut therapies: CBT and gut-directed hypnotherapy

Two psychological therapies have RCT-grade evidence specifically for IBS. Cognitive behavioural therapy adapted for IBS (CBT-IBS) targets the cognitive and behavioural patterns that maintain symptoms; in a large UK randomised trial it produced clinically significant improvement in 71% of patients (Everitt 2019, PMID 30765267). Gut-directed hypnotherapy (GDH) delivered on the Manchester Protocol uses suggestion and imagery to recalibrate visceral signalling and gut-brain regulation; in an unselected sample of 1,000 consecutive refractory IBS patients, 76% responded with at least 50% symptom improvement (Miller 2015, PMID 25736234).

In a head-to-head randomised trial reported by Peters 2016 (PMID 27397586), gut-directed hypnotherapy and the low-FODMAP diet produced equivalent symptom relief, with both interventions delivering significant and clinically meaningful improvement and no statistically significant difference between arms at 6-month follow-up. This positions GDH and low-FODMAP as comparable first-tier options on outcome, with different practical profiles. GDH wins on long-term ease (no permanent dietary restriction); low-FODMAP wins on rapid initial response in some subtypes.

Why GDH is in the major guidelines for confirmed IBS

Both NICE (UK) and the British Society of Gastroenterology now list gut-directed hypnotherapy as an evidence-based option for patients with confirmed IBS who have inadequate response to first-line dietary and pharmacological treatment. CBT-IBS sits alongside it. The presence of these therapies in the guidelines reflects two things: the consistency of the trial data across multiple research groups, and the favourable safety and tolerability profile compared with long-term medication or restrictive diets.

For patients researching this option, the practical introduction is on the page covering what gut-directed hypnotherapy is, with deeper coverage on GDH for IBS. Both pages assume you have a confirmed Rome IV diagnosis and walk through what the protocol actually involves, what the response window looks like, and how to assess fit.

Hypnotherapy is generally not directly covered under Canadian extended health benefit plans. Some clients can claim related programs (stress management, behavioural change) under a Wellness Spending Account (WSA) if their plan offers one. Coverage rules depend entirely on plan design, so check with your insurance provider before booking.